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Abstract Cytoskeletal homeostasis is essential for the
development, survival and maintenance of an efficient
nervous system. Microtubules are highly dynamic poly-
mers important for neuronal growth, morphology,
migration and polarity. In cooperation with several classes
of binding proteins, microtubules regulate long-distance
intracellular cargo trafficking along axons and dendrites.
The importance of a delicate interplay between cytoskeletal
components is reflected in several human neurodegenera-
tive disorders linked to abnormal microtubule dynamics,
including Parkinson’s disease (PD). Mounting evidence
now suggests PD pathogenesis might be underlined by
early cytoskeletal dysfunction. Advances in genetics have
identified PD-associated mutations and variants in genes
encoding various proteins affecting microtubule function
including the microtubule-associated protein tau. In this
review, we highlight the role of microtubules, their major
posttranslational modifications and microtubule associated
proteins in neuronal function. We then present key evi-
dence on the contribution of microtubule dysfunction
to PD. Finally, we discuss how regulation of microtubule
dynamics with microtubule-targeting agents and deacety-
lase inhibitors represents a promising strategy for
innovative therapeutic development.
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Introduction
PD is a neurodegenerative disorder characterised by sig-
nificant degeneration of dopaminergic neurons within the
substantia nigra pars compacta of the midbrain [1, 2]. It is
the second most common neurodegenerative disease, with
a general prevalence of 0.3 % in industrialised countries
[3]. PD aetiology is complex and still poorly understood.
Environmental exposure and genetic predisposition con-
tribute to the incidence of the disease, but ageing remains
the major risk factor. The prevalence increases from 1 %,
in people over 60 years of age, to 4–5 % in individuals
over 80 years of age [3, 4]. Most commonly, patients
develop late-onset PD between the age of 60 and 70, but
some cases are diagnosed before the age of 50, classified as
early onset PD [5]. A number of studies suggest also higher
prevalence amongst men than women, although these
findings remain controversial [3]. Around 90 % of PD
cases are sporadic, but the continuing discovery of several
causative mutations linked to familial forms of PD may
also improve understanding of the pathogenesis in sporadic
cases [3, 6, 7]. Over the last 20 years, genome-wide
association studies and genetic analysis identified numer-
ous loci containing causative mutations and PD risk
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variants. Some of these mutations are causative for PD,
others for clinically similar parkinsonian syndromes [8].
The cardinal parkinsonian symptoms of progressive
bradykinesia, rigidity and resting tremor have long been
described [9]. Though PD is regarded as foremost a
movement disorder, there are a number of well-described
non-motor symptoms, such as autonomic dysfunction,
sleep disturbance, depression, cognitive decline and
dementia [10]. Moreover, a variety of molecular and cel-
lular pathways have been suggested to play a role in the
pathogenesis of PD. These include, but are not limited to,
accumulation of misfolded protein aggregates associated
with proteasomal and autophagic dysfunction, neuroin-
flammation, mitochondrial damage and oxidative stress
[11–14]. Development of effective interventional therapies
currently poses a major challenge partially due to the
diversity of affected molecular pathways and lack of con-
sensus on which mechanisms might constitute the primary
insult leading to PD. Currently, dopaminergic transmission
is partially restored in a majority of newly diagnosed
patients by administration of the neurotransmitter precursor
levodopa [15]. Although there are temporary improve-
ments in symptoms, the levodopa therapy tends to lose
efficacy over time and often leads to debilitating side
effects [15–17]. Long-term studies have shown that early
co-administration of bromocriptine may delay the onset of
side effects [18, 19]. Despite having produced significant
improvements in PD patients, particularly at early stages,
levodopa therapy remains a non-disease-modifying
approach.
Mounting evidence suggests that deregulation of
neuronal cytoskeleton function constitutes a key insult
during the pathogenesis of neurodegenerative diseases.
Understanding the fine regulation of cytoskeletal com-
ponents particularly important for microtubule dynamics,
axonal transport and synaptic function is a crucial first
step to unravel dysfunctional mechanisms leading to
neurodegeneration. Microtubules form intracellular
transport highways, which allow trafficking of molecular
cargo along axons to facilitate neuronal function.
Dynamic reorganisation of microtubules has long been
known to mediate essential aspects of cellular home-
ostasis, including mitosis, vesicular transport, organelle
and protein trafficking as well as maintenance of struc-
tural integrity. Microtubule dysfunction is increasingly
viewed as important contributor to PD pathogenesis.
Lewy bodies, a classical histological feature of PD, have
been found to contain tubulin and neurofilaments, key
elements of the neuronal cytoskeleton [20–22]. More-
over, multiple lines of evidence suggest that the PD-
associated proteins a-synuclein, parkin, PINK1 and the
Leucine-rich repeat kinase 2 (LRRK2) may modify
microtubule stability [23–26]. Here, we outline the role
of microtubules within neuronal function, their post-
translational modifications and associated proteins. We
further explore the evidence linking microtubule dys-
function to PD, before discussing recent advances in the
possible use of microtubule targeting therapeutics for
neurodegenerative diseases.
Microtubules
Structural overview
Microtubules are highly dynamic intracellular polymers. In
close association with F-actin, they form an integral com-
ponent of the neuronal cytoskeleton [27]. As well as
controlling neuronal morphology, the cytoskeleton also
regulates trafficking and cell division [28]. Microtubules
are assembled modularly from a/b-tubulin heterodimers, of
which six and seven isoforms are currently described,
respectively [27, 29]. This composition generates polarity
in microtubules, with growth and shrinkage occurring at
the plus end [27, 30], although minus end polymerisation
has also been observed [28]. At the core of this process is a
tight balance of growth and shrinkage referred to as
dynamic instability (Fig. 1a) [31, 32].
Primary assembly of GTP-bound a/b-tubulin hetero-
dimers generates linear protofilaments bound to a template
structure known as the c-tubulin ring complex [33, 34].
The c-tubulin complex caps the microtubule minus end
resulting in microtubule growth from the plus end. The
intradimeric, a-tubulin-bound GTP occupies the ‘non-ex-
changeable’ site (N-site), and exerts a fixed structural role
[35, 36]. Heterodimers are bound to the growing plus end
via a-tubulin interaction with an interdimeric GTP mole-
cule, bound to b-tubulin at the ‘exchangeable’ site (E-site)
(Fig. 1b) [27, 36]. The GTP cap must remain at the fore-
most plus end for efficient assembly, and is therefore
hydrolysed to GDP upon binding of a new GTP-bound
heterodimer, effectively shifting upwards in position.
Protofilaments then laterally assemble into a circular array
with 13-fold symmetry, resulting in a tubular structure
approximately 15–25 nm in diameter (Fig. 1a). Hydrolysis
of the E-site GTP cap results in a longitudinal strain along
the microtubule, facilitating disassembly of the protofila-
ments and release of free a/b-tubulin heterodimers
[36, 37]. Although the exact structural nature of this pro-
cess has long remained elusive, it has recently been shown
that loss of the E-site GTP leads to compression of the
interdimeric interface, with resultant instability [36]. The
GTP-dependence inherent to tubulin polymerisation is
primarily responsible for its dynamic nature. Self-nucle-
ation of microtubules in the presence of GTP is observable
in vitro [38], although multiple accessory proteins facilitate
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this highly energy dependent process intracellularly
[28, 29, 39].
In neurons, microtubules, actin filaments and neurofila-
ments compose the cytoskeleton, maintaining cell polarity,
architecture and morphology [40]. Microtubule bundles are
spread throughout the soma, dendrites and axon, connect-
ing these different compartments [30]. The axonal shaft
displays uniform plus end orientation, while dendrites
possess more variable combinations [27, 30]. Microtubules
also have a prominent role in growth cone function, a
Fig. 1 Microtubule structure and dynamic instability. Microtubules
are long, dynamic, cylindrical polymers with a diameter of 15–25 nm.
Each microtubule is composed by 13 protofilaments of a/b-tubulin
heterodimers, which assemble forming a tubular structure (a). At
microtubule plus ends, GTP-bound b-tubulin caps growing filaments,
attracting further GTP-bound a/b-tubulin heterodimers. Upon binding
of a new heterodimer, b-tubulin GTP on the filament undergoes
hydrolysis at the ‘exchangeable’ site (E-site), ensuring the GTP cap
remains on the first heterodimer (b) [27, 36]. The cyclic incorporation
and loss of GTP b-tubulin, stochastically alternates growing (rescue)
stable and depolymerising states (catastrophe). The ‘non-exchange-
able’ site (N-site) is occupied by the intradimeric, a-tubulin-bound
GTP, and ensures structural stability [35, 36]. Crystal structure of
tubulin from PDB [http://www.rcsb.org/pdb/pv/pv.do?pdbid=
1TUB&bionumber=1], mechanism adapted from [36]
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highly dynamic process directing axonal growth during
neuronal development (Fig. 2). The complex process of
axon outgrowth requires spontaneous electrical activity
provided by calcium and sodium channels [41–43] as well
as a set of specific growth cone receptors interpreting
external guidance cues [44]. Activation of growth cone
receptors triggers intracellular signalling pathways leading
to the formation of a ‘molecular clutch’ [45]. This complex
links receptors to the F-actin cytoskeleton present in the
periphery of growth cones [45, 46]. Here, dynamic
microtubules are tethered to F-actin filaments through a
variety of cross-linking proteins [27, 47]. Examples include
the plus-tip interacting protein (?TIP) class, which mediate
axonal extension both in Drosophila and mouse cortical
neurons through the subfamily of spectraplakins [48, 49].
The centre of growth cones is composed of stable micro-
tubule bundles, which are surrounded by a dynamic F-actin
network [50]. The cytoskeletal composition within growth
cones determines their shape and movement during
development. F-actin filaments exert pressure on the
plasma membrane via a ‘treadmilling’ mechanism of
directional assembly and disassembly [27, 44]. At the same
time, microtubules are guided and effectively pulled along
the direction of F-actin polymerisation, both outwardly and
Fig. 2 Cytoskeletal distribution in growth cones. At the growth cone,
F-actin extends the plasma membrane forming filopodia and
polymerises in bundles. These F-actin bundles associate with dynamic
and growing microtubules to promote axon outgrowth. Stable micro-
tubule bundles are present in the centre of growth cones
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in retrograde flow [44]. The combination of these processes
results in remodelling and/or extension of the neuronal
plasma membrane [51, 52]. The importance of axonal
outgrowth and growth function for late-onset neurodegen-
erative diseases is currently unclear but it should be noted
that changes in neurite outgrowth and growth cone mor-
phology in genetic PD models have been observed, for
example, in LRRK2 PD models [23, 53–55].
Post-translational modifications of microtubules
Microtubule dynamics and therefore stability are primarily
regulated through a number of post-translational modifica-
tions (PTMs) of tubulin, both in its heterodimeric and
protofilament conformation (Fig. 3). Multiple modifications
often occur simultaneously and vary depending on cell type
and subcellular localisation. Such complexity results in the
generation of microtubules with spatially and temporally
dependent characteristics. PTMs also regulate microtubule
binding to a high number of proteins, further contributing to
tight regulation of neuronal cytoskeletal dynamics. Here, we
focus on current evidence surrounding some of the well-
described PTMs which have been observed to play a role in
microtubule function: tyrosination, polyglutamylation,
acetylation as well as generation of D2-tubulin (Fig. 3) [29].
We would like to stress that the significance of the findings
discussed below for physiological and pathogenic events
remains controversial in nature.
In 1975, Arce et al. identified tyrosination as the first
PTM of tubulin [56], characterising the incorporation of
Fig. 3 Post-translational modifications of tubulin. Overview of post-
translational modifications (PTMs) of tubulin including target sites,
associated enzymes and known effects. Microtubules in subcellular
compartments are functionally and structurally distinguished, with
stable and dynamic axonal microtubules presenting differential PTM
distributions
Back to the tubule: microtubule dynamics in Parkinson’s disease
123
tyrosine onto the a-tubulin C-terminal in rat brain homo-
genates [56]. The reversibility of this reaction was
described by Hallak et al. shortly after [57]. Interestingly,
a-tubulin is tyrosinated in its nascent state [58], with the
cyclic addition and removal of C-terminal tyrosine (dety-
rosination) constituting its primary modification. The
carboxypeptidase responsible for a-tubulin detyrosination
remains unidentified at present. Moreover, its tyrosinating
counterpart tubulin tyrosine ligase (TTL) is far better
characterised [59–62]. TTL acts exclusively on a/b het-
erodimers and is thought to tyrosinate all soluble tubulin
prior to microtubule polymerisation. Thus, all assembling
microtubules are solely composed of tyrosinated tubulin.
This notion is strongly suggestive of correct microtubule
assembly being dependent on tyrosination. In accordance,
selective knockout of TTL expression has been shown to
induce death in mice at 1 day of age [63]. TTL ablation
resulted in widespread disturbance of neuronal organisa-
tion, with prominent disruption of cortico-thalamic
circuitry acting as a likely candidate for lethality [63].
TTL-null cultured neurons also exhibit morphological
abnormalities, including excessive neurite outgrowth with
premature axon differentiation [63]. Similarly, Marcos
et al. reported that TTL knockout in precerebellar neurons
results in aberrant filopodia projections and enlarged
growth cones, with significantly altered localisation of
myosin and actin filaments as well as microtubules [64].
Unsurprisingly, these cellular areas are rich in tubulin
polymerisation.
At the molecular level, tubulin lacking a C-terminal
tyrosine functional group exhibits a greater capacity for
recruitment of motor proteins over its tyrosinated coun-
terparts. Kinesins, a class of molecular motors responsible
for trafficking along microtubules, have been reported to
bind the exposed glutamate subunit of detyrosinated
microtubules with 2.8-fold higher binding affinity relative
to tyrosinated microtubules [65]. Immunofluorescence
imaging of modified kinesin heavy chain (KIF5C) has
shown that kinesin-1 preferentially binds and traffics along
detyrosinated microtubules in neuronal cell lines [66]. In
2009, Konishi and Setou proposed that the relative abun-
dance of detyrosinated in comparison to tyrosinated tubulin
in neurons may act as a candidate mechanism for directing
kinesin-1 to specific neuronal cellular compartments.
Kinesin-1 is typically confined to axonal regions of neu-
rons. Konishi et al. reported that inhibition of TTL via
siRNA knockdown in rat hippocampal neurons resulted in
a decrease in tubulin tyrosination, and a subsequently
broader distribution of microtubule-associated kinesin-1 to
both axonal and dendritic cellular compartments [67].
Microtubules with long turnover times appear enriched
with detyrosinated tubulin, associating detyrosination with
increased microtubule stability [68]. Intriguingly, whilst
detyrosination might be necessary for increased stability, it
does not appear to be a sufficient condition [69, 70]. ?TIPs
have also been shown to differentially bind to detyrosi-
nated microtubules. In mammalian fibroblasts, cytoplasmic
linker protein (CLIP) 170 shows higher affinity for
tyrosinated microtubules, whereas detyrosination of a-
tubulin inhibits CLIP170 binding [71, 72]. These findings
are strongly suggestive of tyrosination as a key mechanism
mediating microtubule protein–protein interactions. More
recent evidence suggests that detyrosinated microtubules
may play a modulatory role in striated muscle mechan-
otransduction [73]. Moreover, detyrosinated tubulin may
upregulate X-ROS signalling, a transduction pathway
through which reactive oxygen species (ROS) are produced
in response to mechanical stress. In Duchenne muscular
dystrophy (DMD), a rare X-linked condition, alterations to
microtubule dynamics lead to detrimental enhancement of
X-ROS signalling with downstream disruption of calcium
signalling. Kerr et al. demonstrate that in vivo inhibition of
detyrosination through TTL overexpression reduces stress
induced X-ROS and calcium signalling in a DMD mouse
model [73].
Detyrosination of a-tubulin exposes the C-terminal
glutamate which is further removed by the enzyme deg-
lutamylase. Deglutamylation subsequently generates the
D2-tubulin isoform. Removal of the TTL binding, C-ter-
minal glutamate residue renders this tubulin isoform
resistant to tyrosination. In contrast to detyrosination, this
PTM is irreversible. Despite D2-tubulin represent-
ing *35 % of total brain tubulin, its functional role
remains largely unclear [74]. An early characterisation
study localised D2-tubulin to early differentiating neurons
and growth cones [75]. D2-tubulin is also largely confined
to highly stable structures such as centrosomes and primary
cilia. Similar to tyrosination, however, removal of C-ter-
minal glutamate might simply correlate with enhanced
microtubule stability [75].
First described in 1990, polyglutamination is a major
PTM capable of generating further diversity in tubulin [76].
Employing a combination of HPLC and mass spectrometry
on mammalian brain, Edde´ et al. observed the addition of
glutamate residues close to the C-terminal end of a-tubulin
[76]. Shortly thereafter, several groups demonstrated
independently that this modification also occurs on b-
tubulin [77–79]. Glutamination of both a and b tubulin
occurs over two phases. First, ‘initiation’ reaction catalyses
the formation of a covalent bond conjoining the c-carboxyl
group of the modified glutamate and the amine group of the
added glutamate residue. Glutamate residues are subse-
quently incorporated as part of a secondary ‘elongation’
reaction to form acidic side chains of varying length [80].
Polyglutamylases, driving polyglutamination, are large
proteins containing TTL-like (TTLL1) catalytic subunits
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[81]. Polyglutamylase subunit 1 (PGs1) has been identified
through immunoprecipitation assays with mouse brain
tubulin [82]. Although PGs1 is not directly linked to
enzymatic activity, it is significantly enriched in hotspots
of polyglutaminated microtubules—namely mitotic spin-
dle, neuronal microtubule, axonomes and centrioles
[80, 83, 84]. As such, PGs1 has been suggested as adaptor
for recruitment of a larger polyglutamylase complex. The
ROSA22 mouse, which exhibits loss of functional PGs1
activity, may offer indirect insight into the role of polyg-
lutamylated microtubule [83, 84]. These mice display
significantly reduced microtubule polyglutamylation in
neurons alongside abnormal sperm flagella, heightened
intermale aggressive behaviour and a reduction in body fat
content [84]. Subsequent in-depth analysis of ROSA22
mutants revealed decreased binding of a-tubulin with
several MAP and kinesin-3 motor proteins, although
kinesin-1 and kinesin-2 binding appeared unaltered [83].
Similar to other tubulin PTMs, it is likely that polyglu-
tamination impacts trafficking and microtubule dynamics
through differential recruitment of molecular motor pro-
teins and MAPs [85, 86].
Acetylation has long been considered to be specific to a-
tubulin, occurring on the luminal surface of microtubule
protofilaments at the lysine 40 residue [87]. More recently,
however, Chu et al. identified the lysine 252 residue of b-
tubulin as a novel acetylation site. This PTM is catalysed
by the acetyltransferase San at the polymerisation interface
[88]. At present, however, evidence remains limited as to
the functional significance of b-tubulin acetylation. Inter-
estingly, cryo-electron microscopy analysis of
protofilament distribution indicates that a-tubulin acetyla-
tion does not appear to alter microtubule architecture or a-
tubulin confirmation significantly. Howes et al. suggest
instead that acetylation might regulate luminal protein–
protein interactions within microtubules [89]. Deacetylase
and acetyltransferase enzymes are considered to be
responsible for tight regulation of a-tubulin de-/acetylation,
respectively. In 2002, Hubbert et al. first identified histone
deacetylase class II (HDAC6) as an a-tubulin deacetylase
[90]. The authors observed in vivo a-tubulin deacetylation
following HDAC6 overexpression [90]. Conversely,
siRNA-mediated HDAC6 knockdown enhances lysine 40
acetylation [90]. These findings were further corroborated
by Zhang et al., who reported a direct interaction between
HDAC6 and b-tubulin in a yeast-two hybrid assay. HDAC6
mediated a-tubulin deacetylation was also observed in
mouse embryonic stem cells within the same study [91]. It
is important to point out that histone deacetylases are not
tubulin-specific enzymes. They additionally target chro-
matin with modulatory effects on chromosomal function.
This notion should be considered when assessing off-target
effects of pharmacological agents affecting deacetylation.
Sirtuin 2 (SIRT2), an additional tubulin deacetylase has
been shown to interact with soluble heterodimers as well as
assembled microtubules [92]. Interestingly, the oxidative
neurotoxin 6-hydroxydopamine (6OHDA) was shown to
influence SIRT2 activity and microtubule dynamics
through more than one mechanism, leading to impaired
nuclear import of certain transcription factors [93, 94].
Consistently, altered subcellular localisation of transcrip-
tion factors has been reported in post-mortem PD brains
[93, 95, 96].
Acetyltransferase activity, responsible for a-tubulin
acetylation, was first described in Chlamydomonas flagel-
lar [97]. In mammalian cells, acetylation is reportedly
catalysed by a-tubulin acetyltransferase 1 (aTAT1) or by
n-a-acetyltransferase A (NatA) [98]. Despite the available
evidence, the exact mechanism by which acetyltransferases
and deacetylases gain access to lysine 40 is not fully
understood. Nogales et al. suggested slow diffusion of
acetyltransferase down the lumen of assembled micro-
tubules as a candidate mechanism [87]. An alternative
model proposes that variability in lateral protofilament
interactions may result in transient, localised openings of
the microtubule wall. This model has been likened to a
‘breathing’ mechanism following cryo-electron micro-
scopy observation of small structural defects in
microtubule walls [99, 100].
Akin to tyrosination, acetylation has been implicated in
control of cellular trafficking, with particular relevance to
recruitment and activity of motor proteins [90, 101]. Reed
et al. reported that loss of a-tubulin acetylation modifies
kinesin-1 binding and trafficking activity in vitro [102].
Increased a-tubulin acetylation is also observed during
axogenesis, suggesting its potential role in axonal growth
and neuronal plasticity [101].
Microtubule-mediated axonal transport
Microtubules form intracellular highways along which
organelles, vesicles and proteins are constantly trafficked.
The unique architecture of neurons, set apart by their long
axons and dendrites, has posed the evolutionary need for a
tightly organised microtubule network able to ensure effi-
cient long-range transport. Unsurprisingly, altered
microtubule regulation was shown to be an early event in
neurodegenerative diseases associated with axonal trans-
port defects [103–108].
Axonal transport is chiefly described as the active
movement of subcellular structures along neuronal micro-
tubules (Fig. 4) [109, 110]. In a 1948 seminal study, Weiss
and Hiscoe first demonstrated its existence in chicken
sciatic nerves [111]. Correct sorting of cargos and orga-
nelles requires tight regulation of this cellular mechanism
at multiple levels [112]. Axonal transport is classified into
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fast and slow, according to cargo speed. Furthermore,
directionality of movement away from, or towards the
soma is used to distinguish anterograde from retrograde
axonal transport, respectively [113]. ATP dependent motor
proteins and a multitude of kinases regulate this complex
process. Kinesins, first purified in 1985 from the squid
axoplasm, are a large family of motor proteins essentially
involved in anterograde transport [114]. Structurally,
kinesins are cytosolic proteins with two globular heads,
binding ATP and microtubules, connected to a cargo
binding tail domain (Fig. 4, left). The remarkable binding
specificity of kinesins arises from an extremely diverse
population of tail domain binding motifs. The ‘stepwise’
movement of kinesins along microtubules is an energy
dependent process requiring ATP hydrolysis [115].
Dynamic association and dissociation of these molecular
Fig. 4 Microtubule-mediated axonal transport. Axonal microtubules
are specialised in transmitting vesicles and other cargo via molecular
motors. Microtubule organisation and modulation by MAPs (such as
tau) also aids transport. Kinesin (left red) performs anterograde
transport to axonal terminals. Dynein (right yellow) moves
retrogradely towards the cell body. Fast and slow axonal transports
drive organelles, vesicles and proteins along the axon. A tight balance
of anterograde, bidirectional and retrograde transport is required to
avoid either accumulation or depletion of cellular components [40]
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motors is also dependent on local microtubule concentra-
tion, the presence of kinases and adaptor proteins
[113, 116].
Anterograde transport is associated with axonal growth
and synaptic vesicle replenishment [117]. Synaptic vesi-
cles, dense core vesicles, brain-derived neurotrophic factor
(BDNF) containing vesicles and amyloid precursor protein
(APP) exemplify the heterogeneity of cargo actively traf-
ficked along the axon via anterograde transport [40]. The
kinesin-3 family, particularly the motor proteins KIF1A
and KIF1B, is known to be involved in this transport
modality [118]. Fast anterograde transport is responsible
for movement of vesicles emerging from the Golgi, at an
average speed of 200–400 mm per day [40]. Administra-
tion of transport blocking antimitotic agents, namely
colchicine and vinblastine, has been employed to demon-
strate the essential role of microtubules in axonal transport
[119]. By contrast, cytosolic proteins and cytoskeletal
polymers such as neurofilaments and tubulin itself are
shuttled at much slower speeds of 0.1–3 mm per day [113].
Retrograde transport, primarily mediated by cytoplasmic
dyneins (Fig. 4, right), is associated with intracellular
recycling and injury signalling [120]. Dynein is composed
of two heavy chains, intermediate, light intermediate and
light chains [40]. Large microtubule binding protein com-
plexes (MBPs) such as dynactin are responsible for
tethering cargo to dyneins. Additionally, an array of
adaptor proteins, of which lissencephaly-1 and huntingtin
are prime examples, contributes to this process [113]. A
number of ?TIPs and end binding proteins, such as EB1
and EB2, are recruited to the highly dynamic microtubule
plus ends thus facilitating active loading of dynein-cargo
complexes [121]. Signalling endosomes, autophagosomes
and injury signalling molecules are transported retro-
gradely towards the cell soma [120]. Microtubule
instability and impaired axonal transport have been sug-
gested to cause incomplete fusion of autophagosomes with
lysosomes leading to autophagic vesicle accumulation
[122]. Arduino and others also reported defects in autop-
hagic vesicle mobilisation towards lysosomes due to
disruption of microtubule dependent trafficking [123].
Overall, axonal transport regulates the functional distribu-
tion of several proteins through remarkably diverse cargo
binding specificity. This notion also implies that a large
variety of disease-associated proteins are likely to interact
with microtubules.
The role of tau in health and disease
Mutations and variants in the MAPT gene, encoding the
microtubule-associated protein tau, as well as deposition of
misfolded tau as neuropathological correlate have been
linked to several neurodegenerative diseases, such as
familial frontotemporal dementia with parkinsonism linked
to chromosome 17 [124], progressive supranuclear palsy
[125], chronic traumatic encephalopathy [126], amy-
otrophic lateral sclerosis (ALS) [127], Alzheimer’s disease
(AD) and PD [121–123, 128, 129].
Microtubule dynamics are heavily dependent on an
array of microtubule-associated proteins (MAPs) selec-
tively and transiently decorating axonal microtubules. Both
microtubule orientation and MAP subset are determinants
of transport directionality and organelle sorting. Accord-
ingly, axons and dendrites differ by their MAP subset. An
important example is the differential distribution of two
well-described MAPs: MAP2 and tau. While MAP2 is
predominant in dendritic microtubules, tau is relatively
more abundant in axons [30].
Tau is encoded by the MAPT gene located on chromo-
some 17q21 [130]. It associates with axonal microtubules
to promote stability, although unbound tau is also found in
the cytosol [131, 132]. In the human brain, tau isoforms
ranging from 352 to 441 amino acids are generated through
alternative splicing [131].
Tau protein structure can be divided into a highly acidic
N-terminal projection domain, a central proline-rich region
and a C-terminal domain. The N-terminus interacts with
other cytoskeletal elements and the plasma membrane. The
C-terminus usually contains three to four highly homolo-
gous 31-32 amino acid repeats functioning as binding
domains [133]. Amongst these, the KXGS motif is critical
for microtubule interaction as well as regulation of tau
folding and aggregation. Furthermore, the tau N-terminal
projection domain has long been proposed to affect axonal
microtubule spacing and diameter [134]. Recent high-res-
olution in vitro polymerisation studies, suggest that tau
may also influence microtubule-actin network cross-linking
[135]. It was further shown that tau promotes tubulin
polymerisation and actin bundling in vitro [134, 136].
Microtubule assembly is heavily dependent on the tau
phosphorylation state; given a dephosphorylated tau con-
formation is necessary for polymerisation [137].
Consequently, research efforts have focused on the iden-
tification of tau regulatory kinases and phosphatases
influencing microtubule binding. Most described tau
kinases are proline directed protein kinases including
glycogen synthase kinase 3b (GSK3b), MAP kinase
(MAPK), cdc2 and cdk5. Specifically, serine 262 and
threonine 231 phosphorylation at the microtubule binding
site significantly reduces microtubule binding resulting in
filament disassembly [136, 138].
Perhaps expectedly, tau actively participates in axonal
transport and neurite outgrowth [139, 140]. Through
competition for microtubule binding sites with molecular
motors, it may in fact prevent or reduce organelle and
cargo trafficking [141]. PTMs of tau, reportedly
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phosphorylation and acetylation [142], exert a modulatory
action on tau function, thus influencing microtubule sta-
bility. Mass spectrometry analysis identified a lysine-rich
region in the microtubule binding site as a key acetylation
site [142]. In the same study, both acetylation and phos-
phorylation appear to induce tau release from microtubules,
in turn leading to an enriched pool of cytosolic tau prone to
aggregation. In addition, loss of tau acetylation, an event
enhancing tau phosphorylation, has been observed in AD
patients and a murine model of tauopathy [143]. Studies in
transgenic models expressing mutant tau suggest that loss
of tightly regulated phosphorylation state results in
microtubule destabilisation and abnormal tau aggregation
[144, 145]. Intracellular tau accumulation can generate
inclusions termed paired helical filaments (PHF) further
assembled in neurofibrillary tangles (NFT) in AD
[146, 147]. In addition to AD, hyperphosphorylated tau
aggregates are a classical feature in a number of neurode-
generative diseases [128, 132, 133, 148]. In the context of
PD, Lewy bodies are well-known to contain tau and a-
synuclein, a notion suggestive of a pathological interaction
between the two proteins [149]. Accordingly, a direct tau-
a-synuclein interaction has previously been reported [150].
In addition, protein kinase A and GSK3b have been pro-
posed as kinases mediating a-synuclein-dependent tau
phosphorylation [151, 152]. This process may result in
microtubule depolymerisation and reduced axonal
transport.
Mutations in MAPT have been described in frontotem-
poral dementia (FTD) with Parkinsonism and progressive
supranuclear palsy [153, 154]. The importance of tau in
neurodegeneration was further supported by genome-wide
association studies identifying MAPT as risk factor for
sporadic PD [154, 155]. In addition, the H1 MAPT haplo-
type is significantly associated with increased susceptibility
to PD [153, 155].
Microtubule dysfunction in Parkinson’s disease
A growing body of evidence suggests abnormal neuronal
cytoskeleton assembly and function as key processes in
neurodegenerative disease. Several proteins linked to
neurodegenerative diseases including PD have been
reported to bind tubulin directly and/or modulate micro-
tubule stability (Fig. 5) [23–25, 156]. Here, we focus on
evidence surrounding a number of key microtubule-inter-
acting proteins—parkin, PTEN induced putative kinase 1
(PINK1), leucine-rich repeat kinase 2 (LRRK2) and a-
synuclein (SNCA). Mutations in all corresponding genes
cause autosomal forms of Parkinsonism [157]. Figure 5
summarises the major effects of PD-linked proteins on
microtubules.
The parkin gene encodes a member of the E3 ubiquitin
ligase family, which targets proteins for proteasomal
degradation [158]. Exonic deletions in parkin were first
identified in association to early onset autosomal recessive
Parkinsonism in three unrelated Japanese families [159].
Physiological tubulin folding is dependent on the
activity of multiple chaperone proteins. Dysfunctional
protein folding machinery can induce toxic accumulation
of misfolded tubulin heterodimers. Ren et al. reported that
parkin enhances a/b-tubulin ubiquitination and clearance
via a direct interaction [156]. In the same study, PD-as-
sociated parkin loss of function mutations was shown to
abolish tubulin ubiquitination. This observation is sugges-
tive of a potential pathogenic mechanism, although further
investigation is required to verify these findings. In a later
study, the authors reported high affinity parkin-tubulin
binding via the linker (partially corresponding to RING0),
RING1 and RING2 domains [24]. These interactions were
subsequently shown to partially rescue colchicine-induced
microtubule depolymerisation. Perhaps surprisingly, the
microtubule-stabilising properties of parkin appear not to
be compromised by PD-linked mutations [24]. A more
recent publication further characterised the structure of
human parkin, comprising four domains: UDP (Unique
Parkin Domain, also known as RING0), RING1, IBR (In
Between Ring Domain) and RING2 (Fig. 5) [160]. The
authors reported that the UDP domain co-interacts with
RING1 and RING2, and contains a putative phosphopep-
tide binding site. PD-causing mutations were subsequently
mapped to this site [160]. Parkin was further shown to
decrease MAP kinase activity, reducing microtubule
depolymerisation [161]. This mechanism may be neuro-
protective to midbrain dopaminergic neurons, a cell
population highly vulnerable to microtubule depolymeri-
sation [162]. Interestingly, PD-linked parkin mutations
appear to abolish this effect [161].
Parkin has also been reported to regulate mitochondrial
trafficking for subsequent degradation (mitophagy)
[163, 164]. This mechanism is reportedly dependent on
inhibitory phosphorylation of the mitochondrial Rho
GTPase (Miro) [163, 165]. Miro, a calcium-binding
GTPase, facilitates kinesin association with mitochondria,
enabling their anterograde transport [166, 167]. Particu-
larly, it is tethered to the mitochondrial surface via the
adaptor protein milton. This interaction gives rise to a
multi-protein complex binding kinesin heavy chain
[168, 169]. Its inhibition results in release of mitochondria
from kinesin (Fig. 5, middle left) [163, 166]. Miro phos-
phorylation is chiefly mediated by the serine/threonine
kinase PINK1. Parkin-directed mitochondrial degradation
thus appears to be PINK1-dependent [163, 170–172].
Wang et al. proposed an elegant functional hypothesis to
account for this mechanism: PINK1/parkin-mediated
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mitochondrial transport arrest may serve as ‘quality con-
trol’, restricting motility to functional mitochondria [163].
It has been in fact previously shown that PINK1 is selec-
tively cleaved into DN-PINK1 at active mitochondrial
surfaces and subsequently degraded [173–175]. Interest-
ingly, DN-PINK1 may also bind parkin to provide negative
feedback inhibition of mitophagy. Together, these findings
suggest mitochondrial activity may be an essential
requirement for its efficient transport. This suggests that
PD-linked loss of function mutations in PINK1 and parkin
allow aberrant transport of dysfunctional mitochondria, a
process likely deleterious to neuronal viability in the long
term. The precise molecular mechanism by which PINK1
and parkin regulate mitochondrial transport and ubiquiti-
nation endogenously remains elusive, however [176].
Upstream of PINK1, the serine/threonine MAP/micro-
tubule affinity regulating kinase 2 (MARK2) has been
identified as a regulatory enzyme [177]. Phosphorylation of
Fig. 5 Effect of PD-linked proteins on microtubules. Overview of
microtubule effects mediated by mutations in known PD-related
genes, including inheritance patterns. All of the discussed proteins
have demonstrated varying degrees of tubulin binding and the ability
to modify microtubule function via several distinct mechanisms.
Parkin structure adapted from [160]
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the cleavage product DN-PINK1 by MARK2 was shown to
promote anterograde mitochondrial motility [177, 178].
The authors also employ imaging to report PINK1 and
MARK2 co-localisation with mitochondria, predominately
within axons and dendrites. Whilst lacking a mitochondrial
localisation signal, DN-PINK1 has also been shown to
influence dendrite but not axonal morphology via interac-
tion with MAP2 [179, 180].
Leucine-rich repeat kinase 2 (Fig. 5, centre) is another
example of a microtubule-interacting protein with rele-
vance to PD. Encoded by LRRK2, it is a large protein with
overlapping functions in microtubule dynamic and intra-
cellular signalling. LRRK2 contains kinase and GTPase
(Roc-COR) domains, as well as multiple protein–protein
interaction sites [181]. Mutations and variants in LRRK2
are implicated in both autosomal dominant and sporadic
PD [157, 182, 183]. All pathogenic mutations are located in
the LRRK2 Roc-COR GTPase or LRRK2 kinase domain,
and encompass single amino acid substitutions.
One of the most consistently observed effects of LRRK2
mutations on the cytoskeleton is impaired neurite out-
growth [53, 184, 185]. Nonetheless, it is unclear if this is
due to LRRK2 mediated changes in tubulin phosphoryla-
tion, tubulin acetylation, MAP phosphorylation and/or
microtubule associated protein kinase regulation. Early
in vitro experiments in HEK293 cells revealed LRRK2 co-
localisation with b-tubulin [186]. We have also previously
shown LRRK2 co-localisation with microtubules in growth
cones [23, 187]. In this subcellular compartment, LRRK2
may also regulate the balance between stabilised and
destabilised actin filaments [188]. Gillardon further repor-
ted that LRRK2 phosphorylates bovine brain b-tubulin
[189]. Interestingly, phosphorylation was enhanced sig-
nificantly by the pathogenic G2019S mutation in the
LRRK2 kinase domain conferring increased LRRK2
autophosphorylation. We later demonstrated LRRK2
binding to the C-termini of only three out of eight b-tubulin
isoforms possibly conferring some specificity in subcellular
microtubule binding of LRRK2 [23]. Interestingly, this
protein interaction takes place at the luminal microtubule
surface in close proximity to the taxol binding site on b-
tubulin and the lysine 40 a-tubulin acetylation sites.
LRRK2 knockout was further shown to increase a-tubulin
acetylation indicating that LRRK2 binding to microtubules
might interfere with tubulin acetylation. In addition, we
showed that the b-tubulin LRRK2 protein interaction
strength was modulated by LRRK2 mutations. Surprisingly,
some mutations increased, whereas others decreased the
protein interaction indicating that a fine regulation of this
interaction might be required in order to avoid too much as
well as too little a-tubulin acetylation [23]. Godena et al.
more recently showed that both LRRK2 R1441C and
Y1699C selectively bind deacetylated microtubules in vitro
[26]. They suggested that this correlated to the observed
mutation-dependent alterations in axonal transport in rat
cortical neurons. Moreover, cells overexpressing mutant
LRRK2 showed LRRK2 co-localisation with tubulin in
filamentous structures. These mutants also altered axonal
transport and induced motor impairments in Drosophila
[26]. The LRRK2 kinase inhibitor IN-1 has now been
reported to decrease a-tubulin acetylation and reduce
microtubule stability in hybrid human cells [190]. A cor-
responding increase in free a-tubulin was also observed,
consistent with microtubule depolymerisation.
In addition to tubulin, several lines of evidence suggest a
functional interaction between LRRK2 and tau [191]. Tau
neuropathology was reportedly observed in some human
PD brains expressing the Y1699C, G2019S and I2020T
LRRK2 mutations [182, 192–194]. Age-related tau mislo-
calization and hyperphosphorylation have also been
described in transgenic mice carrying the LRRK2 G2019S
or R1441G mutations [195, 196]. Importantly, Kawakami
et al. described LRRK2-mediated tau phosphorylation at
threonine 181 in vitro [184]. This reaction appears to be
limited to tubulin-associated tau, and results in decreased
tubulin binding. The authors propose a model, whereby
LRRK2 controls tau release from microtubules through
phosphorylation. The notion of a pathophysiological tau-
LRRK2 interaction was corroborated in a further study by
Bailey et al. [197]. They demonstrated LRRK2-mediated
tau phosphorylation at a variety of residues in vitro. In
addition, in a tau P301L mouse model, expression of
LRRK2 significantly increased deposition of insoluble,
hyperphosphorylated tau [197]. LRRK2 has also been
found to promote GSK3b activity and enhance tau phos-
phorylation [198, 199]. The above observations are in line
with a tau mediated microtubule destabilising effect of
LRRK2 mutations.
SNCA, encoding a-synuclein (Fig. 5, top right), was the
first gene in which PD-linked dominant mutations were
identified [200]. In addition, duplications and triplications
of SNCA were also found to induce clinically diverse
parkinsonian symptoms, suggesting a gene dose-dependent
pathogenic effect [200, 201]. a-Synuclein accumulates and
aggregates in Lewy bodies, the classical pathological hall-
mark of PD. These aggregates consist of a misfolded a-
synuclein core surrounded by other proteins. A number of
proteins have been found to co-localise with a-synuclein
within Lewy bodies—namely tau, ubiquitin, tubulin as well
as synaptic vesicle and stress-response proteins [202–204].
Some studies have also demonstrated presence of LRRK2,
suggesting an interaction with a-synuclein [205, 206].
LRRK2 has further been suggested as upstream of either a-
synuclein and/or tau phosphorylation [207]. This hypothesis
is supported by LRRK2, a-synuclein and tau all represent-
ing genetic risk factors for sporadic PD [154, 205].
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At present, neuronal a-synuclein function is understood
incompletely. Several studies ascribe a physiological role
of a-synuclein in the regulation of vesicle transport and
dopamine release [208, 209]. a-Synuclein has been shown
to interact with tubulin. Nonetheless, the effect of this
interaction on tubulin polymerization and microtubule
stability is less clear, with some studies suggesting a
resulting increase in tubulin polymerisation whereas others
suggest an impairment of polymerization [25, 210–212].
The result of a-synuclein treatment on neurite outgrowth is
similarly inconclusive. Neurite outgrowth was reported to
be enhanced in neurons treated with or overexpressing
wild-type a-synuclein but not mutant forms of the protein
[213]. By contrast, overexpression of wild-type and mutant
a-synuclein has also been implicated in impaired neurite
outgrowth, microtubule-dependent axonal transport,
autophagy defects, and subsequent axonal degeneration
[214]. Koch et al. suggest that the previously reported
increase in neurite outgrowth [213] might in fact represent
an acute response to exogenous a-synuclein expression.
Conversely, chronically elevated levels of the protein
would result in reduction of neurite length [214]. Inter-
estingly, actin microfilaments and neurofilaments remained
unaltered in another study reporting a-synuclein induced
axonal degeneration [210]. To support this observation, the
authors suggested a microtubule-selective mechanism for
a-synuclein toxicity. On the other hand, tubulin oligomers
reportedly stimulate a-synuclein fibrillogenesis [203].
Mutations in SNCA result in increased formation of a-
synuclein b-sheet structures, resulting in the formation of
toxic oligomers and mature fibrils [215]. In vivo design
and biophysical analysis of fibril-promoting versus oli-
gomer-promoting variants of a-synuclein reveals an
important distinction. While a-synuclein oligomers cor-
relate with neurotoxicity, the mature fibrils appear to be
protective [216]. Accordingly, microtubule depolymeri-
sation induced by mitochondrial dysfunction led to a-
synuclein oligomerisation supporting the idea of an
interdependence of changes in a-synuclein expression,
microtubule depolymerisation and a-synuclein oligomeri-
sation [217]. a-Synuclein has also been found to affect
axonal transport, influencing microtubule stability and
kinesin binding [211]. Consistent with their associated
toxicity, a-synuclein oligomers significantly impair kine-
sin function. In a rat model of a-synucleinopathy, altered
levels of presynaptic and axonal transport protein have
also been observed [218].
Genome-wide association studies also highlighted a link
between SNCA and MAPT, suggesting cooperation in
idiopathic PD pathogenesis [154]. Synucleinopathies with
tau-containing inclusions and vice versa have been repor-
ted, suggesting toxic interaction between tau and a-
synuclein. Cross talk between these two proteins promotes
synuclein fibrillization and increases tau phosphorylation
in vitro and in vivo [219]. A direct interaction between a-
synuclein and tau has also been shown [150]. Moreover,
PD-inducing neurotoxins increase a-synuclein expression
and downstream synuclein-dependent tau phosphorylation
via PKA and GSK3b [152, 212]. The molecular interplay
between a-synuclein, microtubules and tau remain a criti-
cal question.
Finally, the potential interplay between DJ-1 and
microtubules is of note. DJ-1 function is still poorly char-
acterised, and the majority of studies have focused on
effects on mitochondrial function. Current evidence
implicates loss of DJ-1 in mitochondrial fragmentation,
autophagy and oxidative stress [220, 221]. PINK1/parkin-
induced parkinsonian phenotypes are not rescued by DJ-1
expression, suggesting potentially independent pathome-
chanisms [221]. A function for DJ-1 in microtubule
dynamics has recently been revealed. siRNA-mediated
knockdown of DJ-1 resulted in reduced b-tubulin III
expression in neuroblastoma cells [222]. Importantly, a
similar phenotype was observed in DJ-1 knockout mice. In
both DJ-1 deficient model systems, microtubule poly-
merisation was reduced. Abnormal dendritic morphology
was additionally observed in cultured striatal medium
spiny neurons [222]. While these results offer promising
insights into DJ-1 function on microtubules, extensive
investigation into its potential relationship with previously
discussed pathomechanisms is required.
The majority of experiments on the interaction of the
cytoskeleton and familial PD proteins support the idea of a
role of these proteins in the regulation of microtubule
dynamics by different mechanisms including changes in
PTMs of tubulin and tau, and changes in the activity of tau
kinases. These observed changes can result in microtubule
depolymerisation, subsequent impairment of axonal trans-
port, synaptic dysfunction and eventually
neurodegeneration. As the first insult seems to be a loss of
fine regulation of the dynamic instability of microtubules
the idea to use therapeutics strategies that restore this
equilibrium is justified.
Potential therapeutic strategies
Mounting evidence points to cytoskeletal dysfunction as an
underlying mechanism in neurodegenerative diseases,
including PD. Microtubule-oriented therapeutic approaches
have been among the most successful in cancer therapy
[223–225]. Several authors now also indicate microtubules
as promising targets in neurodegenerative diseases
[226, 227]. Here, we present potential therapeutic strate-
gies, focusing on microtubule modulation and control of
cellular signalling.
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Microtubule-targeting agents (MTAs) are a group of
compounds, which variably bind to and modify micro-
tubule function (Fig. 6). Depending on their effect on
polymerisation, they are classified as microtubule stabilis-
ing or destabilising agents. A number of MTAs are in
various stages of preclinical and clinical development
[225]. Examples discussed here include the taxanes, epo-
thilone D and noscapine.
Members of the taxane family of compounds are
amongst the better characterised MTAs. Paclitaxel
(Taxol) was first isolated from T. brevifolia in 1971 [228]
and later identified as a microtubule binding, antimitotic
agent [229–233]. Prolonged paclitaxel treatment has long
been shown to induce microtubule stabilisation and a-
tubulin acetylation [234]. This finding is suggestive of a
mechanism whereby stabilised microtubules might facili-
tate acetyltransferase access to lysine 40. Given the
importance of tubulin acetylation in recruitment of motor
proteins [90, 101, 102], enhanced microtubule stability
may constitute a requirement for efficient axonal transport.
A definitive mechanism for paclitaxel-induced microtubule
stabilisation was proposed in more recent years, ascribing
its effect to luminal b-tubulin binding. Such interaction
induces lateral protofilament stabilisation following a
conformational change at the b-tubulin M-loop [235, 236].
The subsequently named taxane binding site has been the
focus of extensive investigation into a number of com-
pounds with similar binding properties. Two prominent
examples are the epothilones (see below) and zampanolide,
with X-ray crystallography confirming reversible and
covalent binding to the taxane site, respectively [229, 237].
With relevance to neurodegeneration, selective dopamin-
ergic loss in rotenone-induced Parkinsonism is reversed by
paclitaxel [162, 235]. The outcomes of paclitaxel treatment
on axonal transport are diverse, however, and still under
debate. A study by Karbowski et al. has in fact shown that
paclitaxel-induced microtubule stabilisation does not affect
intracellular trafficking and distribution of mitochondria
[238]. Conversely, paclitaxel restored alterations in fast
axonal transport, microtubule detyrosination as well as
motor deficits in tau transgenic mice [139]. An intriguing
explanation for this effect was proposed by the authors,
whereby paclitaxel does not reduce the pathological burden
of tau inclusions per se. Rather, this compound acts as a
functional replacement for sequestered tau [139]. Interest-
ingly, the taxane binding site is also targeted by the
microtubule-binding domain of tau, with paclitaxel induc-
ing tau displacement from microtubules [236, 239].
Despite such effectiveness, a major challenge to paclitaxel
administration is posed by its very poor penetrance of the
blood–brain barrier [240]. To address this issue, synthetic
paclitaxel derivates with an improved delivery profile have
been developed. Examples include cabazitaxel, TPI-287,
and IDN-5109 [241–245]. The paclitaxel-peptide conju-
gate, GRN1005, a paclitaxel-peptide conjugate, was also
recently developed to enhance neuronal delivery. Follow-
ing administration in patients with advanced solid tumours,
the active paclitaxel-GRN1005 complex was detected
within brain metastases [246].
The epothilone family of taxol-like compounds com-
prises blood–brain barrier-penetrant microtubule stabilising
agents which have recently been a research focus in cancer
and neurodegeneration [103, 240, 247]. Similarly to
paclitaxel, their efficacy is thought to originate from
functional replacement of tangle-sequestered tau. Long-
term epothilone D (Epo D) treatment at subcytotoxic doses
restored axonal morphology and microtubule density to
wild-type levels in young PS19 tau transgenic mice. AD-
like cognitive impairments associated with this murine
model were also ameliorated [248]. Similar results were
later obtained in aged PS19 mice, in which Epo D rescued
axonal transport defects and improved cognition [249].
Both studies demonstrate the absence of dose-limiting side
effects, indicating Epo D as a promising candidate for
neurodegeneration therapy. Cartelli et al. later investigated
a similar treatment regimen in a 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) murine model of PD
[103]. These mice display nigrostriatal degeneration with
early PTM alterations in a-tubulin. Dopaminergic loss, as
well as the altered PTMs was both ameliorated following
systemic, long-term Epo D injections [103]. The authors
argue that disruption of neuronal microtubule dynamics
may constitute an early, preclinical event in PD patho-
genesis, supporting the notion of microtubule stabilisation
as a valid therapeutic approach. A recent study has further
highlighted the neuroprotective properties of Epo D [250].
In vitro modelling of axonal transection injury now
demonstrates a dose-dependent enhancement of post-injury
recovery. Particularly, Epo D improves axonal sprout
number significantly while growth kinetics remains unaf-
fected. The authors also report cultured neurons to remain
viable throughout a wide dose range. This observation
confirms the relatively low toxicity of Epo D doses at
which microtubule-stabilising effects can be achieved.
Noscapine, an opium alkaloid with established antitus-
sive effects [251], is another interesting candidate due to
reported, albeit weak, microtubule-modifying properties
[252–254]. While noscapine does not appear to signifi-
cantly affect microtubule polymerisation or overall
amounts of intracellular tubulin, it has been characterised
as tubulin-binding compound in vitro [253, 255]. Addi-
tionally, a number of noscapine-mediated neuroprotective
effects have been observed. In a SOD1 transgenic mouse
model of ALS, microtubule and axonal transport deficits
are reportedly improved following noscapine treatment
[247]. Particularly, a significant reduction in microtubule
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turnover rate was observed in association with delayed
disease onset and improved motor behaviour. Further
experiments by this group later characterised axonal
transport-mediated cerebrospinal fluid (CSF) secretion of a
number of known cargo proteins, including a-synuclein
and APP [256]. PD patients displayed CSF secretion pro-
files consistent with significant alterations in cargo
transport dynamics. This observation was paralleled in
MPTP-treated as well as A53T SNCA mutant mice.
Interestingly, noscapine treatment significantly improved
the CSF phenotype [256].
Considering the importance of tubulin acetylation in
maintenance of intracellular transport [90, 101], pharma-
cological modulation of this PTM may prove useful in PD
treatment. Histone deacetylase inhibitors (Fig. 6) have long
been employed in psychiatry, and in more recent years as
Fig. 6 Microtubule-targeting agents (MTAs). Overview of micro-
tubule targeting agents as potential therapeutic strategies. A variety of
compounds has been shown to exert beneficial effects on microtubule
PTMs, stability and transport. Additionally, the outlined agents are all
reportedly able to produce improvements in PD-associated, model
phenotypes. MTAs are also characterised by low toxicity at micro-
tubule-modifying doses [Reference for chemical structures: https://
www.ncbi.nlm.nih.gov/pccompound]
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antimitotic agents. Because of the functional overlap of
histone acetyltransferases in structural control of both
chromatin and tubulin, the aforementioned class of com-
pounds has indeed proven capable of altering microtubule
function. Treatment of hippocampal neurons with tricho-
statin A, a histone deacetylase I-II inhibitor, has been
shown to direct kinesin-1-mediated JIP1 transport to neu-
rite tips [102]. A recent study characterised microtubule
dysfunction in Rett syndrome, a rare neurodevelopmental
condition [257]. In patient-derived fibroblasts, reduced a-
tubulin acetylation was observed in correlation with
increased expression of HDAC6. Additionally, microtubule
polymerisation was markedly decreased. A similar phe-
notype was also observed in Rett syndrome mouse models.
Administration of tubastatin A, an HDAC6 inhibitor, was
then investigated. Within both model systems, pharmaco-
logical inhibition of HDAC6 restored a-tubulin acetylation
levels. The polymerisation phenotype was also amelio-
rated, albeit to a more limited extent [257]. Taken together,
these compelling data suggest targeting of deacetylated a-
tubulin as a promising therapeutic strategy in Rett syn-
drome. Translating this approach to PD, however, demands
further insight into a potential microtubule-mediated
pathomechanism.
In this respect, the study by Godena et al. introduced in
the previous section is of relevance [26]. Drosophila axo-
nal transport and locomotor deficits induced by PD-
associated LRRK2 mutations were reversed by trichostatin
A, tubastatin A or AGK2, a SIRT2 inhibitor [26]. As
mentioned previously, abnormal filamentous LRRK2 was
detected in marked co-localisation with tubulin. These
aberrant structures were suppressed by deacetylase inhi-
bitor treatment in HEK293 cells and rat cortical neurons.
Furthermore, aTAT1 expression also prevents the mutant
phenotype [26]. In accordance with these data, another
study reports on a partial phenotype rescue in a 1-methyl-4-
phenylpyridinium (MPP?)-induced zebrafish PD model
[258]. This fish suffers from impaired locomotion and
sensorimotor reflexes, as well as lowered cellular metabolic
rate. Both tubastatin A and MS-275—a synthetic HDAC1
inhibitor—rescued the metabolic phenotype. Both inhibi-
tors, however, failed to improve locomotion [258]. The
authors thus highlight the need for further studies in models
of genetically induced PD to clarify potential confounding
factors. In the wider context of neurodegeneration, mouse
models of ALS [259], AD [260] and Charcot–Marie–Tooth
(CMT) disease [261] may also benefit from HDAC6 inhi-
bition. In all cases, deacetylase inhibitor therapy resulted in
symptomatic alleviation. However, it should be noted that
oxidative stress induced by the neurotoxin 6OHDA also
reduces deacetylase activity via inhibition of SIRT2 [94].
This finding indicates that therapeutic effects of deacety-
lase inhibition may be context-dependent. An emerging
trend suggests that control over cellular signalling path-
ways upstream of microtubule function might also
constitute an effective therapeutic approach in neurode-
generative disease. Here, we present evidence on two key
pathways: neurotrophic factor-dependent and Wingless/Int-
1 (Wnt) signalling.
Accumulating evidence increasingly supports modula-
tion of neurotrophic factors (NTFs) as a potential strategy in
protecting dopaminergic neurons from insult [262–264].
Jiang et al. evaluated the neuroprotective effects of three
common NTFs: nerve growth factor (NGF), BDNF and glia
cell line-derived neurotrophic factor (GDNF) [265]. The
authors employed rotenone and colchicine-mediated mod-
elling of dopaminergic loss in cultured midbrain neurons.
These model systems display extensive microtubule
depolymerisation and death of tyrosine hydroxylase-positive
neurons. Such phenotype further reiterates the importance of
a functional microtubule network in neuronal viability. In all
cases, neurotrophic factor treatment significantly attenuated
toxicity and restored microtubule polymerisation. The latter
effect is ascribed by the authors to activation of microtubule-
associated protein kinase kinase (MEK). Conversely, MEK
inhibition abolished NTF-mediated neuroprotection [265].
To date, several clinical trials have investigated GDNF
treatment in PD patients [262, 266]. However, results have
so far been inconclusive [267]. In 2006, Salvatore et al.
highlighted difficulties in midbrain drug delivery as a
potential explanation for inefficacy of GDNF [268]. More
recent work investigating viral vectors for sustained NTF
delivery has offered promising results [269]. A number of
studies have also investigated the effect of HDAC inhibi-
tors on NTF gene expression. Valproate, known as
antiepileptic agent, reportedly increases GDNF and BDNF
expression in midbrain neuronal-astrocyte cultures by tar-
geting HDAC2 [270]. Neuroprotection from MPP? toxicity
was achieved concomitantly. A similar outcome was later
observed with an expanded range of HDAC inhibitors
[271]. Due to the relatively broad spectrum of enzyme
inhibition of HDAC inhibitors, it is worth pointing out that
enhanced NTF gene expression might result from a his-
tone-dependent mechanism unrelated to microtubules. A
comparative analysis of expression profiles under a range
of MTA treatments could offer insight into this mechanism.
Three independent highly conserved Wnt signalling
pathways have been described: the canonical pathway
plays key roles in gene expression via transcriptional
activation of b-catenin, the noncanonical/planar cell
polarity pathway (PCP) controls cytoskeletal rearrange-
ment in development through activation of Rho GTPase
and Jun N-terminal kinase (JNK) and the Wnt/Ca2? path-
way modulates cytosolic calcium levels [181, 272].
Although functionally distinguishable, all three share sen-
sitivity to the Wnt family of ligands.
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Wnt signalling exerts control over microtubule dynam-
ics [181, 273] and midbrain dopaminergic neuronal
development [274]. The pathway is generally well char-
acterised in the context of nervous system development. Its
finely regulated activity provides axonal guidance and
remodelling, control of dendrite morphology and synapse
formation [275, 276]. Interestingly, all of these mecha-
nisms are heavily dependent on cytoskeletal function [277].
In this respect, Wnt-mediated regulation of cell polarity has
been characterised in mouse embryonic fibroblasts [278].
The authors indicate that GSK3b, dishevelled (DVL) and
axin—three key Wnt components—are required for
translocation of the centrosome to the leading edge of
polarising cells. Additionally, adenomatous polyposis coli
(APC), a further Wnt protein, were previously revealed to
accumulate and bind to microtubule plus ends [279].
Moreover, APC interaction with membrane components
leads to microtubule polarisation [280]. In embryonic
neuronal tissue, Wnt signalling appears to interact with
actin-microtubule tethering mechanisms [281]. This pro-
cess is reportedly mediated by microtubule actin cross-
linking factor 1 (MACF1). Homozygous silencing of the
corresponding gene is lethal early in embryonic develop-
ment. The authors describe a phenotype similar to ablation
of Wnt ligand production. Moreover, MACF1 was revealed
to participate in translocation of key Wnt components to
the membrane in a putative microtubule-dependent process
[281].
Some of the PD-related proteins, discussed previously,
have been reported to affect Wnt signalling—namely par-
kin [282], PINK1 [283] and LRRK2 [187, 284]. For the
latter, multiple interactions have been described. LRRK2
appears to bind low density lipoprotein receptor-related
protein 6 (LRP6), axin1, GSK3b, b-catenin and DVL 1-3
[187, 284]. Consequently, it was proposed to serve as a
scaffolding protein facilitating Wnt signalling activation
[284]. Indeed, expression of LRRK2 directly enhances b-
catenin transcriptional activity [54, 284]. The aforemen-
tioned PD-associated, Roc-COR LRRK2 mutations appear
to partly abolish this effect while modulating LRRK2-
LRP6 interaction [54]. Interestingly, Godena et al. reported
on axonal transport disruption and locomotor defects
induced by these mutations, as previously discussed [26].
By inference, microtubule/LRRK2/Wnt interplay might
indeed constitute an additional candidate mechanism for
molecular regulation of axonal transport [23, 191, 285].
Further investigation is required to establish the extent of
this interaction, for instance, by determining whether the
LRRK2 mutation-mediated effects on Wnt signalling can
be rescued by microtubule-stabilising therapy. Investiga-
tors also propose pharmacological modulation of the Wnt
signalling pathways as a potential strategy in PD treatment
[274, 286]. These pathways are extremely complex,
however, and target diverse cellular mechanisms. Their
functional heterogeneity is a potential confounding factor,
and needs to be taken into account when investigating cell-
wide effects of Wnt signalling modulation.
Discussion and concluding remarks
We have discussed key evidence surrounding microtubule
dysfunction in neurodegenerative disease, with particular
focus on PD. A multitude of proteins and pathways of
varying functional relationships with microtubules seem to
be implicated in parkinsonian phenotypes. PD-linked pro-
teins involved are associated with mitochondrial transport
[163, 165], microtubule assembly and stability [25, 211],
dynamics [187] and association of motor proteins [141].
Furthermore, their aberrant activity results in impairment
of axonal transport, neurite outgrowth and generally
induces morphological abnormalities in neurons [26, 54].
All of these proteins are able to interact with microtubules,
either directly or via adaptor and motor proteins. Arguably,
any protein which is transported along microtubules will
ultimately bind them through a variety of mechanisms. In
relation to PD, this line of reasoning warrants the following
question: Is the specific function of the involved proteins
the primary cause of toxicity, or do transport defects induce
pathology downstream?
To initially address this issue, we propose a ‘traffic
wave’ model of microtubule dysfunction in PD, and by
extension, neurodegenerative disease. This constitutes an
attempt to account for the diversity of microtubule-asso-
ciated processes which lead to impaired neuronal function.
Traffic wave disturbances in travel propagate and intensify
retrogradely in relation to traffic direction. Generally, they
result in perturbations significantly larger than the initial
‘insult’, and travel backwards for extended distances. We
propose that a similar phenomenon, or rather the long-term
accumulation of transportation defects, may ultimately
result in (a) disruption of cytoskeletal architecture and
(b) loss of functional localisation of any protein or orga-
nelle whose transport is secondarily delayed/affected.
There are a number of observations which lend credi-
bility to this line of reasoning. As previously discussed,
both tau and a-synuclein associate with microtubules and
tau has been shown to promote axonal transport
[25, 139, 140, 213]. Tau exerts an antagonistic action on
motor protein binding. Its functional loss due to aggrega-
tion could therefore induce excessive motor protein
binding. This may also subsequently result in higher
amounts of motor-bound cargo. Accumulation of motor
proteins may reduce transport speed and propagate retro-
gradely as a concentration gradient. Indeed motor protein
gradients are known to directly determine the directionality
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of microtubule transport and movement [287]. The alter-
nation between anterograde and retrograde transport is
dependent on relative concentrations of dynein and kinesin.
Uncoordinated directional switches caused by altered gra-
dients may decrease transport efficiency. This might
ultimately lead to an unpredictable array of functional
consequences. One prominent example could be delay in
delivery of functional mitochondria, depriving parts of the
cell of efficient energy production. Considering that
molecular motors are dependent on local ATP gradients
[115], retrogradely propagating changes in energy avail-
ability may also progressively reduce the ability of
microtubules to deliver cargo to subcellular compartments.
In addition, changes in tau or a-synuclein phosphorylation
state are known to affect microtubule polymerisation [137].
A slower polymerising microtubule may induce accumu-
lation of anterograde cargo at the plus end. This might in
turn propagate backwards along the microtubule and fur-
ther impair transport.
The discussed LRRK2-mediated effects might also aid
corroboration of this model. For example, Godena et al.
demonstrated a mutation-dependent decrease in axonal
trafficking [26]. At the same time, however, mutant
LRRK2 was seen in close association to microtubules, far
more so than WT LRRK2. It may be argued that axonal
transport is slowed down by actual physical interference of
mutant LRRK2 with the microtubule network which, in
turn, retrogradely propagates delays in transport. Given the
discussed importance of fine regulation of tubulin PTMs, a
cargo-crowded microtubule might indeed be more imper-
vious to enzymatic access. Changes in acetylation or
phosphorylation status, for instance, might propagate ret-
rogradely and ultimately destabilise microtubules.
The current outlook on therapeutic strategies is also of
relevance. Most, if not all microtubule-oriented approaches
share a common principle: stabilisation of microtubules
appears to be beneficial [226, 227]. While these agents do
not necessarily target the pathological burden of PD-linked
proteins—e.g., aggregate formation—they do restore
appropriate axonal transport and consequently ensure cargo
delivery. Their beneficial effects might therefore be due to
maintenance of functional localisation of virtually any
protein transported along microtubules.
In conclusion, intracellular transport alterations may
induce secondary damage not always in functional relation
to the protein originally causing the defects. Amongst all
cell types, neurons are some of the most heavily dependent
on a functional microtubule network. PD-linked proteins
may, however diverse, be dependent on a shared, micro-
tubule-dependent pathway. Therefore, development of
effective therapies aimed at maintaining a functional
cytoskeleton may constitute an effective approach.
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